Connexin-Based Channels and RhoA/ROCK Pathway in Angiotensin II-Induced Kidney Damage

IF 2.1 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System Pub Date : 2019-06-22 DOI:10.5772/INTECHOPEN.87040

G. Gómez, V. Velarde, J. Sáez

{"title":"Connexin-Based Channels and RhoA/ROCK Pathway in Angiotensin II-Induced Kidney Damage","authors":"G. Gómez, V. Velarde, J. Sáez","doi":"10.5772/INTECHOPEN.87040","DOIUrl":null,"url":null,"abstract":"The incidence of chronic kidney diseases is increasing worldwide, and there is no efficient therapy to reduce this phenomenon. The main therapies currently available focus on the control of blood pressure and the optimization of the blockade of the renin-angiotensin system (RAS). In addition, it is known that in several models of kidney damage, the amounts of connexins are altered. On the other hand, fasudil, a selective ROCK blocker, has shown renoprotective effects. The beneficial effects of blocking the RhoA/ROCK pathway in renal function may be related to its action of reducing macrophage infiltration, inflammation, and oxidative stress (OS), its expression of extracellular matrix genes and proteinuria, or to its effects on connexin abundance. Even though a correlation has been found between renal damage, caused by an increase in the RAS activity, connexins, and the RhoA/ROCK signaling pathway, it has not yet been possible to clearly determine its functional significance. Moreover, it has not been possible to identify the preponderance of this signaling pathway in the development of chronic kidney diseases. Here, we describe the advances in this subject.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"22 1","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2019-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Renin-Angiotensin-Aldosterone System","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.87040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 3

Abstract

The incidence of chronic kidney diseases is increasing worldwide, and there is no efficient therapy to reduce this phenomenon. The main therapies currently available focus on the control of blood pressure and the optimization of the blockade of the renin-angiotensin system (RAS). In addition, it is known that in several models of kidney damage, the amounts of connexins are altered. On the other hand, fasudil, a selective ROCK blocker, has shown renoprotective effects. The beneficial effects of blocking the RhoA/ROCK pathway in renal function may be related to its action of reducing macrophage infiltration, inflammation, and oxidative stress (OS), its expression of extracellular matrix genes and proteinuria, or to its effects on connexin abundance. Even though a correlation has been found between renal damage, caused by an increase in the RAS activity, connexins, and the RhoA/ROCK signaling pathway, it has not yet been possible to clearly determine its functional significance. Moreover, it has not been possible to identify the preponderance of this signaling pathway in the development of chronic kidney diseases. Here, we describe the advances in this subject.

查看原文本刊更多论文

基于连接蛋白的通道和RhoA/ROCK通路在血管紧张素ii诱导的肾损伤中

慢性肾脏疾病的发病率在全球范围内呈上升趋势，目前尚无有效的治疗方法来减少这一现象。目前可用的主要治疗方法集中在控制血压和优化肾素-血管紧张素系统(RAS)的封锁。此外，已知在几种肾损伤模型中，连接蛋白的数量发生了改变。另一方面，选择性ROCK阻滞剂法舒地尔显示出肾保护作用。阻断RhoA/ROCK通路对肾功能的有益作用可能与其减少巨噬细胞浸润、炎症和氧化应激(OS)的作用，其细胞外基质基因和蛋白尿的表达，或其对连接蛋白丰度的影响有关。尽管已经发现由RAS活性、连接蛋白增加引起的肾损害与RhoA/ROCK信号通路之间存在相关性，但尚不能明确确定其功能意义。此外，还不可能确定这种信号通路在慢性肾脏疾病的发展中的优势。在这里，我们将描述这一学科的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Renin-Angiotensin-Aldosterone System 医学-外周血管病

CiteScore

6.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： JRAAS is a peer-reviewed, open access journal, serving as a resource for biomedical professionals, primarily with an active interest in the renin-angiotensin-aldosterone system in humans and other mammals. It publishes original research and reviews on the normal and abnormal function of this system and its pharmacology and therapeutics, mostly in a cardiovascular context but including research in all areas where this system is present, including the brain, lungs and gastro-intestinal tract.